Moderna aims to explore vaccines against 15 pathogens threatening global health
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) has committed to advance vaccines targeting 15 pathogens considered as biggest public health risk by the WHO and CEPI into clinical studies by 2025.
The company expects the 15 pathogens to include Chikungunya virus, COVID-19, Crimean-Congo haemorrhagic fever, Dengue, Ebola virus disease, HIV, Malaria, Marburg virus disease, Lassa fever, Middle East respiratory syndrome coronavirus (MERS-CoV), Nipah and henipaviral diseases, Rift Valley fever, Severe fever with Thrombocytopenia syndrome, Tuberculosis, and Zika.

The company launched mRNA Access, a new collaborative enabling researchers around the world to use its mRNA technology platform to pursue research in their own labs on emerging and neglected infectious diseases.
Moderna also said it has expanded commitment to never enforce COVID-19 patents in the Gavi COVAX AMC for 92 low- and middle-income countries
In addition, the company said it entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish its first mRNA manufacturing facility in Africa.
MRNA -0.1% pre-market to $126.34